SCHEMBL12640358

SCHEMBL12640358

O=Cc1ccc(NCc2cncc(F)c2)nc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.43
CYP3A4 P08684 1/20 0.43
DYRK1A Q13627 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
CCNT1 O60563 4/20 0.39
HDAC1 Q13547 1/20 0.39
ADORA2B P29275 2/20 0.38
NAMPT P43490 1/20 0.38
PDPK1 O15530 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPK1 P28482 1/20 0.37
CDK9 P50750 1/20 0.37
VNN1 O95497 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599996 0.82 ADORA2B (0.41) CYP2C9CYP3A4DYRK1ACLK4ALDH1A1
SCHEMBL12640326 0.80 NPC1 (0.50) CYP2C9CYP3A4DYRK1ACLK4ALDH1A1
SCHEMBL19910474 0.80 NOS1 (0.41) CYP2C9ALDH1A1KDM4EHPGDHDAC1
SCHEMBL12675604 0.78 PDPK1 (0.38) CYP2C9CYP3A4DYRK1ACLK4ALDH1A1
SCHEMBL32683449 0.77 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDGPR55HDAC1
SCHEMBL12675596 0.76 CYP3A4 (0.47) CYP2C9CYP3A4DYRK1ACLK4CCNT1
SCHEMBL3685097 0.76 POLB (0.57) CYP3A4CLK4ALDH1A1KDM4EHPGD
SCHEMBL29952768 0.76 POLB (0.57) CYP3A4CLK4ALDH1A1KDM4EHPGD
SCHEMBL12640370 0.76 PDPK1 (0.37) CYP2C9CYP3A4DYRK1ACLK4ALDH1A1
SCHEMBL1268175 0.74 ALDH1A1 (0.59) DYRK1ACLK4ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP2C9 3884/4885CYP3A4 3717/4885DYRK1A 584/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP2C9 3884/4885CYP3A4 3717/4885DYRK1A 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.